Cargando…

Safety and efficacy of peptide receptor radionuclide therapy with (177)Lu-DOTA(0)-Tyr(3)-octreotate in combination with amino acid solution infusion in Japanese patients with somatostatin receptor-positive, progressive neuroendocrine tumors

PURPOSE: Peptide receptor radionuclide therapy (PRRT) with (177)Lu-DOTA(0)-Tyr(3)-octreotate ((177)Lu-DOTATATE) is one of the most reliable treatments for unresectable, progressive neuroendocrine tumors (NETs) with somatostatin receptor expression. We have, for the first time, reported the results o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kobayashi, Noritoshi, Takano, Shoko, Ito, Kenichi, Sugiura, Madoka, Ogawa, Matsuyoshi, Takeda, Yuma, Okubo, Naoki, Suzuki, Akihiro, Tokuhisa, Motohiko, Kaneta, Tomohiro, Utsunomiya, Daisuke, Hata, Masaharu, Inoue, Tomio, Hosono, Makoto, Kinuya, Seigo, Ichikawa, Yasushi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Singapore 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8557155/ https://www.ncbi.nlm.nih.gov/pubmed/34533700 http://dx.doi.org/10.1007/s12149-021-01674-9

Ejemplares similares

Hormonal crises following receptor radionuclide therapy with the radiolabeled somatostatin analogue [(177)Lu-DOTA(0),Tyr(3)]octreotate
por: de Keizer, Bart, et al.
Publicado: (2008)

Multimodal Somatostatin Receptor Theranostics Using [(64)Cu]Cu-/[(177)Lu]Lu-DOTA-(Tyr(3))octreotate and AN-238 in a Mouse Pheochromocytoma Model
por: Ullrich, Martin, et al.
Publicado: (2016)

Effects of therapy with [(177)Lu-DOTA(0),Tyr(3)]octreotate on endocrine function
por: Teunissen, Jaap J. M., et al.
Publicado: (2009)

Bone marrow dosimetry in peptide receptor radionuclide therapy with [(177)Lu-DOTA(0),Tyr(3)]octreotate
por: Forrer, Flavio, et al.
Publicado: (2009)

Nephrotoxicity after PRRT with (177)Lu-DOTA-octreotate
por: Bergsma, Hendrik, et al.
Publicado: (2016)

Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [(177)Lu-DOTA(0),Tyr(3)]octreotate
por: Kwekkeboom, D. J., et al.
Publicado: (2003)

Salvage peptide receptor radionuclide therapy with [(177)Lu-DOTA,Tyr(3)]octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumours
por: van der Zwan, W. A., et al.
Publicado: (2018)

Chemotherapy-Induced Upregulation of Somatostatin Receptor-2 Increases the Uptake and Efficacy of (177)Lu-DOTA-Octreotate in Neuroendocrine Tumor Cells
por: Shah, Rashmi G., et al.
Publicado: (2021)

Cellular dosimetry of [(177)Lu]Lu-DOTA-[Tyr(3)]octreotate radionuclide therapy: the impact of modeling assumptions on the correlation with in vitro cytotoxicity
por: Tamborino, Giulia, et al.
Publicado: (2020)

Implementation of patient dosimetry in the clinical practice after targeted radiotherapy using [(177)Lu-[DOTA0, Tyr3]-octreotate
por: Santoro, Lore, et al.
Publicado: (2018)

177Lu-DOTA-0-Tyr3-octreotate infusion modeling for real-time detection and characterization of extravasation during PRRT
por: Mazzara, Christophe, et al.
Publicado: (2022)

Enhancing the anti-tumour activity of (177)Lu-DOTA-octreotate radionuclide therapy in somatostatin receptor-2 expressing tumour models by targeting PARP
por: Cullinane, Carleen, et al.
Publicado: (2020)

Manual on the proper use of lutetium-177-labeled somatostatin analogue (Lu-177-DOTA-TATE) injectable in radionuclide therapy (2nd ed.)
por: Hosono, Makoto, et al.
Publicado: (2018)

In Vivo Measurement and Characterization of a Novel Formulation of [(177)Lu]-DOTA-Octreotate
por: Bailey, Dale L, et al.
Publicado: (2016)

Phase I study of the (177)Lu-DOTA(0)-Tyr(3)-Octreotate (lutathera) in combination with nivolumab in patients with neuroendocrine tumors of the lung
por: Kim, Chul, et al.
Publicado: (2020)

Subacute haematotoxicity after PRRT with (177)Lu-DOTA-octreotate: prognostic factors, incidence and course
por: Bergsma, Hendrik, et al.
Publicado: (2015)

Patient-specific image-based bone marrow dosimetry in Lu-177-[DOTA(0),Tyr(3)]-Octreotate and Lu-177-DKFZ-PSMA-617 therapy: investigation of a new hybrid image approach
por: Gosewisch, Astrid, et al.
Publicado: (2018)

Distinct In Vitro Binding Profile of the Somatostatin Receptor Subtype 2 Antagonist [(177)Lu]Lu-OPS201 Compared to the Agonist [(177)Lu]Lu-DOTA-TATE
por: Mansi, Rosalba, et al.
Publicado: (2021)

Intraindividual comparison of [(177)Lu]Lu-DOTA-EB-TATE and [(177)Lu]Lu-DOTA-TOC
por: Hänscheid, Heribert, et al.
Publicado: (2021)

Rapid kit-based (68)Ga-labelling and PET imaging with THP-Tyr(3)-octreotate: a preliminary comparison with DOTA-Tyr(3)-octreotate
por: Ma, Michelle T., et al.
Publicado: (2015)

Peptide receptor radionuclide therapy (PRRT) with [(177)Lu-DOTA(0),Tyr(3)]octreotate in combination with RAD001 treatment: further investigations on tumor metastasis and response in the rat pancreatic CA20948 tumor model
por: Bison, Sander M, et al.
Publicado: (2014)

Binding of TS1, an anti-keratin 8 antibody, in small-cell lung cancer after (177)Lu-DOTA-Tyr(3)-octreotate treatment: a histological study in xenografted mice
por: Erlandsson, Ann, et al.
Publicado: (2011)

[(177)Lu-DOTA](0)-D-Phe(1)-Tyr(3)-Octreotide ((177)Lu-DOTATOC) For Peptide Receptor Radiotherapy in Patients with Advanced Neuroendocrine Tumours: A Phase-II Study
por: Baum, Richard P., et al.
Publicado: (2016)

Salvage PRRT with (177)Lu-DOTA-octreotate in extensively pretreated patients with metastatic neuroendocrine tumor (NET): dosimetry, toxicity, efficacy, and survival
por: Rudisile, S., et al.
Publicado: (2019)

Comparison of the Anti-Tumour Activity of the Somatostatin Receptor (SST) Antagonist [(177)Lu]Lu-Satoreotide Tetraxetan and the Agonist [(177)Lu]Lu-DOTA-TATE in Mice Bearing AR42J SST(2)-Positive Tumours
por: Plas, Pascale, et al.
Publicado: (2022)

Neuroblastoma xenograft models demonstrate the therapeutic potential of (177)Lu-octreotate
por: Romiani, Arman, et al.
Publicado: (2021)

Validation of Quality Control Parameters of Cassette-Based Gallium-68-DOTA-Tyr3-Octreotate Synthesis
por: Sammartano, Antonino, et al.
Publicado: (2020)

Accuracy and reproducibility of simplified QSPECT dosimetry for personalized (177)Lu-octreotate PRRT
por: Del Prete, Michela, et al.
Publicado: (2018)

(177)Lu-octreotate therapy for neuroendocrine tumours is enhanced by Hsp90 inhibition
por: Hofving, Tobias, et al.
Publicado: (2019)

Potentiation of (177)Lu-octreotate peptide receptor radionuclide therapy of human neuroendocrine tumor cells by PARP inhibitor
por: Purohit, Nupur K., et al.
Publicado: (2018)

Influence of tumour size on the efficacy of targeted alpha therapy with (213)Bi-[DOTA(0),Tyr(3)]-octreotate
por: Chan, Ho Sze, et al.
Publicado: (2016)

Epidemiology of Neuroendocrine Neoplasms and Results of Their Treatment with [(177)Lu]Lu-DOTA-TATE or [(177)Lu]Lu-DOTA-TATE and [(90)Y]Y-DOTA-TATE—A Six-Year Experience in High-Reference Polish Neuroendocrine Neoplasm Center
por: Durma, Adam Daniel, et al.
Publicado: (2023)

Individualisation of radiation protection recommendations for patients treated with [(177)Lu]Lu-DOTA-TATE
por: Monserrat Fuertes, Teresa, et al.
Publicado: (2023)

First-In-Human Results on the Biodistribution, Pharmacokinetics, and Dosimetry of [(177)Lu]Lu-DOTA.SA.FAPi and [(177)Lu]Lu-DOTAGA.(SA.FAPi)(2)
por: Ballal, Sanjana, et al.
Publicado: (2021)

Can the peptide receptor radionuclide therapy [(177)Lu]Lu-DOTA-TATE provide a net benefit for NET patients?
por: Caplin, Martyn E.
Publicado: (2021)

Peptide Receptor Radionuclide Therapy with [(177)Lu]Lu-DOTA-TATE in Patients with Advanced GEP NENS: Present and Future Directions
por: del Olmo-García, Maria I., et al.
Publicado: (2022)

Relationships between uptake of [(68)Ga]Ga-DOTA-TATE and absorbed dose in [(177)Lu]Lu-DOTA-TATE therapy
por: Stenvall, Anna, et al.
Publicado: (2022)

Correlations between [(68)Ga]Ga-DOTA-TOC Uptake and Absorbed Dose from [(177)Lu]Lu-DOTA-TATE
por: Bruvoll, Ragnar, et al.
Publicado: (2023)

Potential Biomarkers for Radiation-Induced Renal Toxicity following (177)Lu-Octreotate Administration in Mice
por: Schüler, Emil, et al.
Publicado: (2015)

Matching-adjusted indirect treatment comparison of [(177)Lu]Lu-DOTA-TATE, everolimus and sunitinib in advanced, unresectable gastroenteropancreatic neuroendocrine tumours: Relative effectiveness of [(177)Lu]Lu-DOTA-TATE in gastroenteropancreatic neuroendocrine tumours
por: Khan, Mohid S., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_kfqqks0fuguvtb0odv5hbqnn55